Enveric Biosciences (ENVB) Delisted from Nasdaq
Ticker: ENVB · Form: 8-K · Filed: Feb 9, 2024 · CIK: 890821
| Field | Detail |
|---|---|
| Company | Enveric Biosciences, Inc. (ENVB) |
| Form Type | 8-K |
| Filed Date | Feb 9, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $2,500,000 |
| Sentiment | bearish |
Complexity: simple
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-action
TL;DR
**ENVB delisted from Nasdaq, expect major liquidity issues and price drop.**
AI Summary
Enveric Biosciences, Inc. (ENVB) announced on February 6, 2024, that its common stock, par value $0.01 per share, will be delisted from The Nasdaq Stock Market. This delisting is due to the company's failure to satisfy continued listing rules, specifically the minimum bid price requirement. This matters to investors because delisting often leads to decreased liquidity and investor confidence, potentially causing a further decline in the stock price and making it harder to buy or sell shares.
Why It Matters
Delisting from a major exchange like Nasdaq can severely impact a company's stock liquidity and investor perception, often leading to a significant drop in share price and making the stock less attractive to institutional investors.
Risk Assessment
Risk Level: high — Delisting from Nasdaq indicates severe financial or operational issues and typically results in a significant loss of investor confidence and liquidity.
Analyst Insight
A smart investor would likely avoid or consider selling ENVB shares due to the severe negative implications of delisting, including reduced liquidity and potential further price depreciation.
Key Players & Entities
- Enveric Biosciences, Inc. (company) — the registrant whose stock is being delisted
- The Nasdaq Stock Market (company) — the exchange from which Enveric Biosciences is being delisted
- $0.01 (dollar_amount) — par value per share of common stock
- February 6, 2024 (date) — date of the earliest event reported regarding the delisting
Forward-Looking Statements
- Enveric Biosciences' stock price will experience significant downward pressure. (ENVB) — high confidence, target: Q1 2024
- Trading volume and liquidity for ENVB shares will decrease substantially. (ENVB) — high confidence, target: Q1 2024
FAQ
What is the primary reason Enveric Biosciences, Inc. is being delisted from Nasdaq?
The filing indicates the delisting is due to 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard', implying a failure to meet Nasdaq's ongoing requirements, such as the minimum bid price.
What is the par value of Enveric Biosciences' common stock?
The common stock of Enveric Biosciences, Inc. has a par value of $0.01 per share, as stated in the filing.
When was the earliest event reported regarding this delisting?
The earliest event reported in this 8-K filing regarding the delisting occurred on February 6, 2024.
What is the trading symbol for Enveric Biosciences, Inc.?
The trading symbol for Enveric Biosciences, Inc. is ENVB, as listed under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the business address of Enveric Biosciences, Inc.?
The business address of Enveric Biosciences, Inc. is 4851 Tamiami Trail N, Suite 200, Naples, FL 34103.
Filing Stats: 832 words · 3 min read · ~3 pages · Grade level 13 · Accepted 2024-02-09 08:05:27
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share ENVB The Nasdaq Stock Mar
- $2,500,000 — holders' equity requirement of at least $2,500,000 as set forth in Nasdaq Listing Rule 555
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-005561.txt ( ) — 208KB
- envb-20240206.xsd (EX-101.SCH) — 3KB
- envb-20240206_lab.xml (EX-101.LAB) — 33KB
- envb-20240206_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 9, 2024 ENVERIC BIOSCIENCES, INC. By: /s/ Joseph Tucker Joseph Tucker, Ph.D. Chief Executive Officer